Agilent launches genomic profiling test SureSelect for solid tumors

Apr. 13, 2023 1:38 PM ETAgilent Technologies, Inc. (A)By: Ravikash, SA News Editor

Agilent Technologies (NYSE:A) said it launched Agilent SureSelect Cancer CGP (Comprehensive Genomic Profiling) Assay for somatic variant profiling for a range of solid tumors.
The pan-cancer test design is based on an NGS panel consisting of 679 genes globally curated from cancer databases and in partnership with cancer researchers, the company added.
The test is automatable and expands the number of biomarkers for solid tumor profiling with a fast and efficient workflow, according to Agilent.
"Library preparation and target enrichment can be automated either on the benchtop Magnis NGS prep system, which will markedly improve workflow efficiency, reducing the hands-on time from hours to only 15 minutes, or on the Bravo NGS workstation, for scaling up to 96 samples per run," said Ronda Allen, vice president and general manager, Genomics Division, Agilent.